Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME).

被引：0
|
作者：
Vermorken, J. B.
Mesia, R.
Vega-Villegas, M. E.
Remenar, E.
Hitt, R.
Kawecki, A.
Rottey, S.
Zabolotnyy, D.
Erfan, J.
Amellal, N.
Antwerpen, U. Z.
机构：
[1] UZ Antwerpen, Edegem, Belgium
[2] Hosp Duran I Reynals Inst Catala Oncol, Barcelona, Spain
[3] Hosp Univ Marques Valdecilla, Santander, Spain
[4] Orszagos Onkol Intezet, Budapest, Hungary
[5] Hosp 12 Octubre, E-28041 Madrid, Spain
[6] Klin Nowotworow Glowy & Szyi, Warsaw, Poland
[7] UZ Gent, Ghent, Belgium
[8] Inst Otolaringol AMS Ukraine, Kiev, Ukraine
[9] Szalbolcs Szatmar Bereg Megyei Josa Andras Korhaz, Nyiregyhaza, Hungary
[10] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：289S / 289S
页数：1
相关论文
共 50 条
  • [1] Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Humblet, Y
    Vega-Villegas, E
    Mesia, R
    Awada, A
    Geoffrois, L
    Borel, C
    Hitt, R
    Amellal, N
    Bessa, EH
    Bourhis, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 491S - 491S
  • [2] Approval Summary: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil for the First-Line Treatment of Patients With Recurrent Locoregional or Metastatic Squamous Cell Head and Neck Cancer
    Cohen, Martin H.
    Chen, Huanyu
    Shord, Stacy
    Fuchs, Chana
    He, Kun
    Zhao, Hong
    Sickafuse, Sharon
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2013, 18 (04): : 460 - 466
  • [3] Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD).
    Knoedler, Maren
    Dietz, Andreas
    Gauler, Thomas Christoph
    Gruenwald, Viktor
    Stoehlmacher, Jan
    Knipping, Stephan
    Guntinas-Lichius, Orlando
    Frickhofen, Norbert
    Schroeder, Michael
    Maschmeyer, Georg
    Rethwisch, Volker
    Haxel, Boris
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Cetuximab, Fluorouracil (5-FU), Ciplatin and Docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCID).
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher-Williams, J.
    Gruenwald, V
    Rethwisch, V.
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2013, 36 : 94 - 94
  • [5] Carboplatin/5-fluorouracil as an Alternative to Cisplatin/5-Fluorouracil for Metastatic and Recurrent Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma
    Kua, Voon Fong
    Ismail, Fuad
    Phua, Vincent Chee Ee
    Aslan, Nik Muhd
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (02) : 1121 - 1126
  • [6] Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and, neck (SCCHN) refractory to first-line platinum-based therapies.
    Vermorken, JB
    Bourhis, J
    Trigo, J
    Kies, M
    Leon, X
    Mueser, M
    Amellal, N
    Schueler, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 501S - 501S
  • [7] PHASE IB TRIAL OF IMO-2055 IN COMBINATION WITH 5-FU, CISPLATIN AND CETUXIMAB IN 1ST-LINE PTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN)
    Machiels, J. P.
    Kaminsky, M. C.
    Keller, U.
    Bruemmendorf, T. H.
    Goddemeier, T.
    Forssman, U.
    Delord, J. P.
    ANNALS OF ONCOLOGY, 2012, 23 : 342 - 342
  • [8] Cisplatin/5-FU 100/1000 in Japanese Patients With Recurrent/Metastatic SCCHN Management of Recurrent Head-and-Neck Squamous Cell Carcinoma
    Tahara, M.
    Onozawa, Y.
    Fujii, H.
    Monden, N.
    Yana, I.
    Otani, S.
    Hasegawa, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 509 - 510
  • [9] Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).
    Friesland, Signe
    Tsakonas, Georgios
    Kristensen, Claus
    Moren, Maria Herlestam Calero
    Haugen, Hedda
    Soderstrom, Karin
    Specht, Lena
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
    Colevas, D. A.
    Misiukiewicz, K.
    Pearson, A. T.
    Fayette, J.
    Bauman, J. R.
    Cupissol, D.
    Saada-Bouzid, E.
    Adkins, D. R.
    Marie, D. B.
    Cornen, S. L.
    Andre, P.
    Carrette, F.
    Rotolo, F.
    Boyer Chammard, A.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S1432 - S1432
12345